These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 34248832)

  • 1. Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue.
    Koska V; Förster M; Brouzou K; Hatami M; Arat E; Aytulun A; Albrecht P; Aktas O; Küry P; Meuth SG; Kremer D
    Front Neurol; 2021; 12():696807. PubMed ID: 34248832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose cyclophosphamide treatment in Marburg variant multiple sclerosis A case report.
    Nozaki K; Abou-Fayssal N
    J Neurol Sci; 2010 Sep; 296(1-2):121-3. PubMed ID: 20579663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An extremely aggressive case of Marburg's disease treated with high dose cyclophosphamide. A case report.
    Avila-Ornelas J; Labat E; Alfonso G; Serrano C; Fiorito F
    Mult Scler Relat Disord; 2019 Jun; 31():51-53. PubMed ID: 30925320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Marburg variant multiple sclerosis with mitoxantrone.
    Jeffery DR; Lefkowitz DS; Crittenden JP
    J Neuroimaging; 2004 Jan; 14(1):58-62. PubMed ID: 14748210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An autopsy case of the Marburg variant of multiple sclerosis (acute multiple sclerosis).
    Suzuki M; Kawasaki H; Masaki K; Suzuki SO; Terada T; Tsuchida T; Tokuyama T; Kono S; Komori T; Baba S; Kira J; Miyajima H
    Intern Med; 2013; 52(16):1825-32. PubMed ID: 23955619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocrelizumab: a new milestone in multiple sclerosis therapy.
    Mulero P; Midaglia L; Montalban X
    Ther Adv Neurol Disord; 2018; 11():1756286418773025. PubMed ID: 29774057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
    Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
    Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
    Stahnke AM; Holt KM
    Ann Pharmacother; 2018 May; 52(5):473-483. PubMed ID: 29232960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphomatosis cerebri masquerading as the Marburg variant of multiple sclerosis.
    AlOhaly N; Nathoo N; Schmitt LM; McCombe JA
    Mult Scler Relat Disord; 2020 Nov; 46():102488. PubMed ID: 32911305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.
    Sorensen PS; Blinkenberg M
    Ther Adv Neurol Disord; 2016 Jan; 9(1):44-52. PubMed ID: 26788130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.
    Vakrakou AG; Tzanetakos D; Argyrakos T; Koutsis G; Evangelopoulos ME; Andreadou E; Anagnostouli M; Breza M; Tzartos JS; Gialafos E; Dimitrakopoulos AN; Velonakis G; Toulas P; Stefanis L; Kilidireas C
    Front Neurol; 2020; 11():536. PubMed ID: 32714265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
    Baker D; Pryce G; James LK; Marta M; Schmierer K
    Mult Scler Relat Disord; 2020 Sep; 44():102279. PubMed ID: 32645640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Additional possible mechanisms of the action of ocrelizumab in multiple sclerosis on example of a case-report].
    Boyko OV; Khoroshylova II; Petrov SV; Lush NY; Guseva ME; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(8. Vyp. 2):116-120. PubMed ID: 30160679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
    Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
    Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies.
    Mecoli CA; Lahouti AH; Brodsky RA; Mammen AL; Christopher-Stine L
    Neurol Neuroimmunol Neuroinflamm; 2017 Sep; 4(5):e381. PubMed ID: 28975138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marburg Multiple Sclerosis Variant: Complete Remission with Very Early Administration of Mitoxantrone-A Case Report.
    Capet N; Levraut M; Delourme A; Thomel-Rocchi O; Bourg V; Cabre P; Vandenbos F; Mondot L; Lebrun-Frenay C
    Neurol Ther; 2022 Mar; 11(1):507-513. PubMed ID: 34859363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.